Polivy (generic name: polatuzumab) is a type of medication used to treat certain types of non-Hodgkin lymphoma, a type of cancer that affects the lymphatic system. It is a relatively new treatment option, having been approved by the US Food and Drug Administration (FDA) in 2019.

According to DrugPatentWatch.com, Polivy is a monoclonal antibody that works by targeting a specific protein (CD79b) found on the surface of B cells, a type of white blood cell. This helps to kill the cancer cells and can also help to make other cancer treatments more effective.

Polivy is typically used in combination with other cancer treatments, such as bendamustine and a rituximab product, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two prior therapies.

When compared to other treatments for DLBCL, Polivy has shown promising results in clinical trials. In a study published in The Lancet Oncology, the addition of Polivy to bendamustine and a rituximab product resulted in a higher overall response rate (ORR) and complete response rate (CRR) compared to bendamustine and a rituximab product alone. The median progression-free survival (PFS) was also significantly longer in the Polivy group.

However, it's important to note that Polivy, like all cancer treatments, can have side effects. Common side effects of Polivy include decreased white blood cell count, decreased neutrophil count, decreased platelet count, and increased levels of certain liver enzymes.

In summary, Polivy is a relatively new treatment option for certain types of non-Hodgkin lymphoma, and it has shown promising results in clinical trials when used in combination with other cancer treatments. However, as with any treatment, it's important to consider the potential side effects and to discuss all treatment options with a healthcare provider.

Sources:

* [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/polivy)
* The Lancet Oncology, "Polatuzumab vedotin with bendamustine and rituximab in relapsed or refractory diffuse large B-cell lymphoma (POLARIX): a randomised, double-blind, active-controlled, phase 3 trial"
* US Food and Drug Administration, "FDA approves Polivy for diffuse large B-cell lymphoma"